Full name
A Phase 4, Open-label, Single Arm, 24-week, Study to Evaluate the Safety and Efficacy of Mepolizumab 100 mg SC Administered Every 4 Weeks in Indian Participants Aged ≥18 Years With Severe Eosinophilic Asthma (PRISM)
NCT Number
NCT04276233
Geography
Non-US
Locations
India
Primary Endpoints
Number of on-treatment adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs). Up to Week 24
External Link
https://clinicaltrials.gov/study/NCT04276233
Order
3
Disease
Version
Phase
4